You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Merck

Last Updated: January 22, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ORE-1001

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ORE-1001?

ORE-1001 is an investigational drug.

There have been 8 clinical trials for ORE-1001. The most recent clinical trial was a Phase 3 trial, which was initiated on August 25th 2017.

The most common disease conditions in clinical trials are Osteoarthritis, Knee, Osteoarthritis, and Cardiovascular Diseases. The leading clinical trial sponsors are Duke University, McGill University Health Center, and Cairo University.

There are three US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for ORE-1001
TitleSponsorPhase
Parabens Flocculation on the Anti Inflammatory Effects of Corticosteroid Injections for Total Knee ArthroplastyLoma Linda UniversityEarly Phase 1
Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy LinesSan Luigi Gonzaga HospitalPhase 2
Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy LinesAzienda Ospedaliera Spedali Civili di BresciaPhase 2

See all ORE-1001 clinical trials

Clinical Trial Summary for ORE-1001

Top disease conditions for ORE-1001
Top clinical trial sponsors for ORE-1001

See all ORE-1001 clinical trials

US Patents for ORE-1001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ORE-1001   Start Trial ACE-2 modulating compounds and methods of use thereof Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
ORE-1001   Start Trial Method for treating inflammatory diseases of the digestive tract Ore Pharmaceuticals Inc. (Cambridge, MA)   Start Trial
ORE-1001   Start Trial Peptide-peptidase-inhibitor conjugates and methods of making and using same Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ORE-1001

Drugname Country Document Number Estimated Expiration Related US Patent
ORE-1001 Australia AU1311300 2018-09-30   Start Trial
ORE-1001 Australia AU3945402 2018-09-30   Start Trial
ORE-1001 Australia AU4500200 2018-09-30   Start Trial
ORE-1001 Australia AU8479401 2018-09-30   Start Trial
ORE-1001 Brazil BR0010166 2018-09-30   Start Trial
ORE-1001 Canada CA2344274 2018-09-30   Start Trial
ORE-1001 Canada CA2372387 2018-09-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.